Back to Montana

HB41 • 2025

Generally revise dangerous drug schedule

Generally revise dangerous drug schedule

Healthcare
Enacted

This bill passed the Legislature and reached final enactment based on the latest official action.

Sponsor
Curtis Schomer
Last action
2025-02-28
Official status
Chapter Number Assigned
Effective date
Not listed

Plain English Breakdown

Checked against official source text during the last sync.

Update List of Dangerous Drugs

This law updates the list of dangerous drugs in Schedule V by adding gabapentin and making other changes.

What This Bill Does

  • Adds gabapentin to the list of controlled substances in Schedule V.
  • Includes specific limits on how much codeine, dihydrocodeine, ethylmorphine, opium, diphenoxylate with atropine sulfate, and difenoxin with atropine sulfate can be in a drug.
  • Lists pyrovalerone as a stimulant that affects the central nervous system.
  • Includes lacosamide, pregabalin, and gabapentin as depressants affecting the central nervous system.

Who It Names or Affects

  • People who use or sell drugs listed in Schedule V.
  • Law enforcement agencies that enforce drug laws.
  • Healthcare providers who prescribe controlled substances.

Terms To Know

Schedule V
A list of dangerous drugs with the least potential for abuse among those regulated by law.
Controlled Substances
Drugs that are regulated by the government because they can be abused or cause harm if not used correctly.

Limits and Unknowns

  • The exact effects of these changes on drug enforcement and public health are unclear.
  • It does not specify how the new rules will affect existing medical treatments involving gabapentin or other listed drugs.

Bill History

  1. 2025-02-28 HOUSE

    Chapter Number Assigned

  2. 2025-02-27 HOUSE

    (H) Signed by Governor

  3. 2025-02-20 SENATE

    (S) Signed by President

  4. 2025-02-20 HOUSE

    (H) Transmitted to Governor

  5. 2025-02-19 HOUSE

    (H) Signed by Speaker

  6. 2025-02-18 HOUSE

    (H) Returned from Enrolling

  7. 2025-02-15 SENATE

    (S) Scheduled for 3rd Reading

  8. 2025-02-15 SENATE

    (S) 3rd Reading Concurred

  9. 2025-02-15 HOUSE

    (H) Sent to Enrolling

  10. 2025-02-14 SENATE

    (S) Scheduled for 2nd Reading

  11. 2025-02-14 SENATE

    (S) 2nd Reading Concurred

  12. 2025-02-07 SENATE

    (S) Committee Report--Bill Concurred

  13. 2025-02-06 SENATE

    (S) Committee Executive Action--Bill Concurred

  14. 2025-02-05 SENATE

    (S) Hearing

  15. 2025-01-21 SENATE

    (S) First Reading

  16. 2025-01-21 SENATE

    (S) Referred to Committee

  17. 2025-01-20 HOUSE

    (H) Scheduled for 3rd Reading

  18. 2025-01-20 HOUSE

    (H) 3rd Reading Passed

  19. 2025-01-20 HOUSE

    (H) Transmitted to Senate

  20. 2025-01-17 HOUSE

    (H) Scheduled for 2nd Reading

  21. 2025-01-17 HOUSE

    (H) 2nd Reading Passed

  22. 2025-01-10 HOUSE

    (H) Committee Executive Action--Bill Passed

  23. 2025-01-10 HOUSE

    (H) Committee Report--Bill Passed

  24. 2025-01-06 HOUSE

    (H) First Reading

  25. 2025-01-06 HOUSE

    (H) Hearing

  26. 2024-12-20 HOUSE

    (H) Referred to Committee

  27. 2024-12-06 HOUSE

    (LC) Draft Delivered to Requester

  28. 2024-12-06 HOUSE

    (H) Introduced

  29. 2024-11-21 HOUSE

    (LC) Draft in Assembly

  30. 2024-11-21 HOUSE

    (LC) Draft Ready for Delivery

  31. 2024-11-20 HOUSE

    (LC) Draft in Input/Proofing

  32. 2024-11-20 HOUSE

    (LC) Draft in Final Drafter Review

  33. 2024-11-19 HOUSE

    (LC) Draft in Legal Review

  34. 2024-11-19 HOUSE

    (LC) Draft in Edit

  35. 2024-11-14 HOUSE

    (LC) Draft Taken Off Hold

  36. 2024-10-16 HOUSE

    (LC) Draft On Hold

  37. 2024-09-06 HOUSE

    (LC) Drafter Assigned

Official Summary Text

Generally revise dangerous drug schedule

Current Bill Text

Read the full stored bill text
****
69th Legislature 2025 HB 41
- 1 - Authorized Print Version – HB 41
ENROLLED BILL
AN ACT REVISING THE LIST OF SPECIFIC DANGEROUS DRUGS INCLUDED IN SCHEDULE V; ADDING
GABAPENTIN TO THE DRUGS LISTED IN SCHEDULE V CONTROLLED SUBSTANCES; AND AMENDING
SECTION 50-32-232, MCA.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:
Section 1. Section 50-32-232, MCA, is amended to read:
"50-32-232. Specific dangerous drugs included in Schedule V. Schedule V consists of the drugs
and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in this
section.
(1) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or
preparation containing any of the following is a narcotic drug, including its salts, calculated as the free
anhydrous base or alkaloid in limited quantities as set forth in subsections (1)(a) through (1)(f), which include
one or more nonnarcotic, active medicinal ingredients in sufficient proportion to confer upon the compound,
mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:
(a) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
(b) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
(c) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
(d) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine
sulfate per dosage unit;
(e) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; and
(f) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate
per dosage unit.
(2) Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any
****
69th Legislature 2025 HB 41
- 2 - Authorized Print Version – HB 41
ENROLLED BILL
material, compound, mixture, or preparation that contains any quantity of pyrovalerone is a stimulant having a
stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers.
(3) Depressants. Unless specifically exempted or excluded or unless listed in another schedule,
any material, compound, mixture, or preparation that contains any quantity of the following substances is a
depressant having a depressant effect on the central nervous system, including its salts, isomers, and salts of
isomers:
(a) lacosamide, also known as (R)-2-acetoamido-N-benzyl-3-methoxy-propionamide or vimpat;
and
(b) pregabalin, also known as (S)-3-(aminomethyl)-5-methylhexanoic acid or lyrica; and
(c) gabapentin, also known as 1-(aminomethyl)cyclohexaneacetic acid.
(4) Anticonvulsant substances include the following:
(a) ezogabine;
(b) brivaracetam;
(c) cenobamate; and
(d) ganaxalone.
(5) Antimigraine substances including lasmiditan."
- END -
I hereby certify that the within bill,
HB 41, originated in the House.
___________________________________________
Chief Clerk of the House
___________________________________________
Speaker of the House
Signed this _______________________________day
of____________________________________, 2025.
___________________________________________
President of the Senate
Signed this _______________________________day
of____________________________________, 2025.
HOUSE BILL NO. 41
INTRODUCED BY C. SCHOMER
BY REQUEST OF THE DEPARTMENT OF JUSTICE
AN ACT REVISING THE LIST OF SPECIFIC DANGEROUS DRUGS INCLUDED IN SCHEDULE V; ADDING
GABAPENTIN TO THE DRUGS LISTED IN SCHEDULE V CONTROLLED SUBSTANCES; AND AMENDING
SECTION 50-32-232, MCA.